Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 209

1.

Short Report: TRPV1-polymorphism 1911 A>G alters capsaicin-induced sensory changes in healthy subjects.

Forstenpointner J, Förster M, May D, Hofschulte F, Cascorbi I, Wasner G, Gierthmühlen J, Baron R.

PLoS One. 2017 Aug 17;12(8):e0183322. doi: 10.1371/journal.pone.0183322. eCollection 2017.

PMID:
28817717
2.

Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?

Culman J, Jacob T, Schuster SO, Brolund-Spaether K, Brolund L, Cascorbi I, Zhao Y, Gohlke P.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Jul 2. doi: 10.1007/s00210-017-1395-y. [Epub ahead of print]

PMID:
28669009
3.

Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine.

Bruckmueller H, Martin P, Kähler M, Haenisch S, Ostrowski M, Drozdzik M, Siegmund W, Cascorbi I, Oswald S.

Mol Pharm. 2017 Jul 3;14(7):2245-2253. doi: 10.1021/acs.molpharmaceut.7b00076. Epub 2017 Jun 2.

PMID:
28510455
4.

Neurodegenerative effects of azithromycin in differentiated PC12 cells.

Waetzig V, Riffert J, Cordt J, Reinecke K, Haeusgen W, Boehm R, Cascorbi I, Herdegen T.

Eur J Pharmacol. 2017 Aug 15;809:1-12. doi: 10.1016/j.ejphar.2017.05.002. Epub 2017 May 4.

PMID:
28479141
5.

Crosstalk control and limits of physiological c-Jun N-terminal kinase activity for cell viability and neurite stability in differentiated PC12 cells.

Waetzig V, Belzer M, Haeusgen W, Boehm R, Cascorbi I, Herdegen T.

Mol Cell Neurosci. 2017 Jul;82:12-22. doi: 10.1016/j.mcn.2017.04.004. Epub 2017 Apr 14.

PMID:
28414095
6.

Activation of the cell membrane angiotensin AT2 receptors in human leiomyosarcoma cells induces differentiation and apoptosis by a PPARγ - dependent mechanism.

LÜtzen U, Zhao Y, Lucht K, Zuhayra M, Hedderich J, Cascorbi I, Culman J.

Neoplasma. 2017;64(3):395-405. doi: 10.4149/neo_2017_310.

PMID:
28253719
7.

Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Sertić J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2017 Feb 16;12(2):e0172595. doi: 10.1371/journal.pone.0172595. eCollection 2017.

8.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.

Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.

9.

Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions.

Böhm R, Cascorbi I.

Front Pharmacol. 2016 Oct 21;7:396. eCollection 2016. Review.

10.

Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.

Lützen U, Zhao Y, Lucht K, Zuhayra M, Marx M, Cascorbi I, Culman J.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Jan;390(1):37-48. doi: 10.1007/s00210-016-1291-x. Epub 2016 Sep 23.

PMID:
27664035
11.

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016. Erratum in: PLoS One. 2017 Feb 16;12 (2):e0172595.

12.

miRNA-187-3p-Mediated Regulation of the KCNK10/TREK-2 Potassium Channel in a Rat Epilepsy Model.

Haenisch S, von Rüden EL, Wahmkow H, Rettenbeck ML, Michler C, Russmann V, Bruckmueller H, Waetzig V, Cascorbi I, Potschka H.

ACS Chem Neurosci. 2016 Nov 16;7(11):1585-1594. Epub 2016 Sep 22.

PMID:
27609046
13.

Advances and challenges in hereditary cancer pharmacogenetics.

Cascorbi I, Werk AN.

Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):73-82. Epub 2016 Sep 16. Review.

PMID:
27603572
14.

Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia.

Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JI, Rees E, Richards AL, Leonenko G, Jorskog LF; Clozapine-Induced Agranulocytosis Consortium, Chambert KD, Collier DA, Genovese G, Giegling I, Holmans P, Jonasdottir A, Kirov G, McCarroll SA, MacCabe JH, Mantripragada K, Moran JL, Neale BM, Stefansson H, Rujescu D, Daly MJ, Sullivan PF, Owen MJ, O'Donovan MC, Walters JT.

Mol Psychiatry. 2016 Jul 12. doi: 10.1038/mp.2016.97. [Epub ahead of print]

15.

Epigenetics in Drug Response.

Cascorbi I, Schwab M.

Clin Pharmacol Ther. 2016 May;99(5):468-70. doi: 10.1002/cpt.349.

PMID:
27061003
16.

HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury.

Nicoletti P, Werk AN, Sawle A, Shen Y, Urban TJ, Coulthard SA, Bjornsson ES, Cascorbi I, Floratos A, Stammschulte T, Gundert-Remy U, Nelson MR, Aithal GP, Daly AK; International Drug-induced Liver Injury Consortium.

Pharmacogenet Genomics. 2016 May;26(5):218-24. doi: 10.1097/FPC.0000000000000209.

PMID:
26959717
17.

Length variants of the ABCB1 3'-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance.

Bruhn O, Drerup K, Kaehler M, Haenisch S, Röder C, Cascorbi I.

Pharmacogenomics. 2016 Mar;17(4):327-40. doi: 10.2217/pgs.15.175. Epub 2016 Feb 19.

PMID:
26895184
18.

Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.

Schirmer JH, Bremer JP, Moosig F, Holle JU, Lamprecht P, Wieczorek S, Haenisch S, Cascorbi I.

Pharmacogenomics. 2016 Mar;17(4):367-74. doi: 10.2217/pgs.15.176. Epub 2016 Feb 19.

PMID:
26894931
19.

Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?

Ingelman-Sundberg M, Cascorbi I.

Clin Pharmacol Ther. 2016 May;99(5):478-80. doi: 10.1002/cpt.351. Epub 2016 Mar 29.

PMID:
26874931
20.

Targeting gene expression during the early bone healing period in the mandible: A base for bone tissue engineering.

Beck-Broichsitter BE, Werk AN, Smeets R, Gröbe A, Heiland M, Cascorbi I, Wiltfang J, Häsler R, Becker ST.

J Craniomaxillofac Surg. 2015 Oct;43(8):1452-60. doi: 10.1016/j.jcms.2015.06.015. Epub 2015 Jun 23.

PMID:
26189147

Supplemental Content

Loading ...
Support Center